JP2022518292A - ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 - Google Patents

ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 Download PDF

Info

Publication number
JP2022518292A
JP2022518292A JP2021543315A JP2021543315A JP2022518292A JP 2022518292 A JP2022518292 A JP 2022518292A JP 2021543315 A JP2021543315 A JP 2021543315A JP 2021543315 A JP2021543315 A JP 2021543315A JP 2022518292 A JP2022518292 A JP 2022518292A
Authority
JP
Japan
Prior art keywords
pde4
epilepsy
inhibitor
pde4b
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518292A5 (https=
JPWO2020154520A5 (https=
Inventor
デボラ エム． クラシュ、
キングズレー イバゼイエボ、
Original Assignee
パス セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パス セラピューティクス，インク． filed Critical パス セラピューティクス，インク．
Publication of JP2022518292A publication Critical patent/JP2022518292A/ja
Publication of JP2022518292A5 publication Critical patent/JP2022518292A5/ja
Publication of JPWO2020154520A5 publication Critical patent/JPWO2020154520A5/ja
Priority to JP2025009888A priority Critical patent/JP2025081323A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04017—3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04035—3',5'-Cyclic-GMP phosphodiesterase (3.1.4.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021543315A 2019-01-23 2020-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 Pending JP2022518292A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009888A JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796002P 2019-01-23 2019-01-23
US62/796,002 2019-01-23
PCT/US2020/014819 WO2020154520A1 (en) 2019-01-23 2020-01-23 Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009888A Division JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Publications (3)

Publication Number Publication Date
JP2022518292A true JP2022518292A (ja) 2022-03-14
JP2022518292A5 JP2022518292A5 (https=) 2023-02-01
JPWO2020154520A5 JPWO2020154520A5 (https=) 2023-02-01

Family

ID=71735544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543315A Pending JP2022518292A (ja) 2019-01-23 2020-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
JP2025009888A Pending JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009888A Pending JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Country Status (6)

Country Link
US (1) US20220098257A1 (https=)
EP (1) EP3914701B1 (https=)
JP (2) JP2022518292A (https=)
CN (1) CN113490739A (https=)
CA (1) CA3127357A1 (https=)
WO (1) WO2020154520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911603D0 (en) * 2019-08-14 2019-09-25 Healx Ltd Treatment
EP4001923B1 (en) 2020-11-23 2024-06-05 Roche Diagnostics GmbH Laboratory sample distribution system and laboratory automation system
EP4249607A1 (en) * 2022-03-21 2023-09-27 Warszawski Uniwersytet Medyczny Panel of markers for prediction of epilepsy recurrence in patients with tuberous sclerosis and the uses thereof
CN121022847B (zh) * 2025-10-31 2026-02-06 温州医科大学附属眼视光医院 一种敲除斑马鱼pde6a的sgRNA及其在视觉疾病中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518924A (ja) * 2004-10-28 2008-06-05 セルジーン・コーポレーション 中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物
US20110230504A1 (en) * 2008-09-15 2011-09-22 The Regents Of The University Of California Office Of Technology ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP
US20130065936A1 (en) * 2010-05-14 2013-03-14 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
JP2016501209A (ja) * 2012-11-30 2016-01-18 レオ ファーマ アクティーゼルスカブ 活性化ｔ細胞におけるｉｌ−２２の発現の阻害方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4999255B2 (ja) * 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド オリゴヌクレオチド含有薬理学的組成物およびその使用
US20050164275A1 (en) * 2002-10-18 2005-07-28 Incyte Corporation Phosphodiesterases
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
EP2037924A2 (en) * 2006-07-07 2009-03-25 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
CA2817290A1 (en) * 2010-11-11 2012-05-18 Josef Penninger Compounds and methods for treating pain
US8865723B2 (en) * 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
EP3766885B1 (en) * 2015-06-17 2022-05-25 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
SG11201806383TA (en) * 2016-02-23 2018-09-27 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518924A (ja) * 2004-10-28 2008-06-05 セルジーン・コーポレーション 中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物
US20110230504A1 (en) * 2008-09-15 2011-09-22 The Regents Of The University Of California Office Of Technology ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP
US20130065936A1 (en) * 2010-05-14 2013-03-14 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
JP2016501209A (ja) * 2012-11-30 2016-01-18 レオ ファーマ アクティーゼルスカブ 活性化ｔ細胞におけるｉｌ−２２の発現の阻害方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF RESEARCH IN PHARMACY PRACTICE, vol. Vol.4,Issue 4, JPN6023053985, 2015, pages 175 - 181, ISSN: 0005585289 *
NANDHAKUMAR, J. ET AL.: "Characterization of the effects of phosphodiesterases (PDEs) isozyme inhibitors in animal models of", LIFE SCIENCES AND MEDICINE RESEARCH, vol. 2010, JPN6023053986, 2010, pages 7 - 1, ISSN: 0005585290 *

Also Published As

Publication number Publication date
EP3914701A1 (en) 2021-12-01
WO2020154520A1 (en) 2020-07-30
EP3914701A4 (en) 2022-10-19
EP3914701B1 (en) 2025-12-03
CN113490739A (zh) 2021-10-08
CA3127357A1 (en) 2020-07-30
JP2025081323A (ja) 2025-05-27
US20220098257A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JP6012591B2 (ja) β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用
JP2025081323A (ja) ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US8007790B2 (en) Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20230116704A1 (en) Antisense oligomers for treatment of conditions and diseases
TW201641691A (zh) Ｔａｕ反義寡聚物及其用途
US10696972B2 (en) Method for improving learning
Seemanová et al. Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability
US11873494B2 (en) Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
Wilson et al. Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury
JPWO2015064768A1 (ja) 角膜内皮の小胞体細胞死関連疾患治療薬
CN101986785A (zh) 治疗和预防神经退行性疾病和紊乱的方法
US20220372489A1 (en) Ppm1a inhibitors and methods of using same
US20230383292A1 (en) Targeting xist and rna methylation for x reactivation therapy
Li et al. Upregulated dynamin 1 in an acute seizure model and in epileptic patients
KR20250087733A (ko) 병태 및 질환의 치료를 위한 화합물
US20190282580A1 (en) Pro-inflammatory role for adenosine uptake and metabolism
Lei et al. PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease
US20180187196A1 (en) Inhibitors of dek protein and related methods
US20150086509A1 (en) Compositions and methods for treating cancer using interferon and mapk pathway inhibitor
US20250136980A1 (en) Modulation of microrna-335-5p for the treatment of sodium channelopathies
WO2020065583A1 (en) Balipodect for treating or preventing autism spectrum disorders
KR20260055532A (ko) 병태 및 질환 치료 방법
JP2025540914A (ja) Ｎｌｒｐ１２およびｎｌｒｃ５モジュレーター、ならびにそれらを使用して疾患を調節する方法
WO2024187097A2 (en) Compositions and methods for modulating sptlc1
WO2024138018A1 (en) Treatment of gemin5-mediated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250123